Summary: The Centers for Medicare & Medicaid Services modified its clinical trials routine costs coverage policy, effective May 15, 2026. Here's what billing teams need to know before that date.
CMS clinical trial billing has always been a minefield. The routine costs coverage policy governs which services Medicare covers when a beneficiary enrolls in a qualifying clinical trial — and when a service gets miscategorized, you're looking at claim denial, overpayment exposure, or both. This modification updates how CMS defines and reimburses routine costs in clinical trials. This policy does not list specific CPT or HCPCS codes; your billing team must apply these rules across whatever codes you already bill for trial-related services.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Routine Costs in Clinical Trials |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Oncology, hematology, cardiology, neurology, any specialty enrolling Medicare beneficiaries in qualifying clinical trials |
| Key Action | Audit your clinical trial billing workflows and modifier use before May 15, 2026 |
CMS Routine Costs in Clinical Trials Coverage Criteria and Medical Necessity Requirements 2026
The CMS clinical trial routine costs coverage policy has a clear premise: Medicare covers the ordinary costs of patient care that would be billed regardless of whether the patient was in a trial. What it does not cover are the experimental costs — the investigational item or service itself, anything provided solely for data collection, and any service the trial protocol requires but that has no established Medicare benefit.
Medical necessity is the dividing line. A service is a routine cost if a Medicare beneficiary not in a trial would typically receive it and it meets medical necessity standards. If the service exists only because the protocol demands it — a lab draw for pharmacokinetic data, an extra MRI required by the study sponsor — it is not a routine cost, and Medicare is not the right payer for that line item.
To qualify for Medicare coverage under this policy, the clinical trial itself must meet specific requirements. The trial must be funded by a qualifying agency (NIH, CDC, AHRQ, CMS, DoD, VA, or similar), or it must have an investigational device exemption or IND from the FDA, or it must meet other qualifying criteria CMS recognizes. Trials that don't clear that bar don't get routine cost coverage — period.
Prior authorization is not a standard feature of clinical trial billing under this coverage policy. However, documentation requirements are strict. Your medical records must show that the specific service billed was a routine cost, not a trial-specific service, and that it met medical necessity criteria independent of the trial protocol.
Medical necessity documentation is not optional here. Auditors know clinical trial billing is a high-error area. CMS and its Medicare Administrative Contractors look at these claims closely. If your documentation doesn't support why a service was medically necessary outside the context of the trial, you'll lose that claim on appeal.
CMS Clinical Trial Billing Exclusions and Non-Covered Indications
This section matters as much as the coverage rules. CMS explicitly excludes certain costs from the routine cost definition, and billing these incorrectly is one of the fastest ways to generate a recovery demand.
The investigational item or service itself is never a routine cost. If the trial is studying a new drug, the drug is not covered. If the trial involves an experimental device, the device is not covered. Your billing team should never submit a claim to Medicare for the item under investigation.
Services required solely to satisfy the research protocol are also excluded. Think of extra clinic visits for data collection, additional blood draws for biomarker panels the sponsor wants, or imaging studies the protocol mandates but that fall outside standard-of-care guidelines. These go to the trial sponsor, not Medicare.
Services that are not otherwise generally available to Medicare beneficiaries are excluded. If Medicare doesn't cover it outside a trial, Medicare doesn't cover it inside a trial as a routine cost.
Anything covered under a Medicare categorical exclusion is still excluded — clinical trial enrollment doesn't override existing coverage denials for specific items or services.
The real issue here is spillover billing: a service that is legitimately medically necessary for the patient but that also happens to serve a protocol purpose. These are the gray-zone claims. If your compliance officer isn't reviewing these regularly, they should be. Talk to your compliance officer before the May 15, 2026 effective date if you're not confident about where your trial billing falls on this line.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Routine patient care services that would be provided regardless of trial participation | Covered | No specific codes listed in this policy | Must meet medical necessity; document independent of trial protocol |
| Investigational item or service being studied in the trial | Not Covered | N/A | Bill to trial sponsor, not Medicare |
| Services required solely for protocol adherence or data collection | Not Covered | N/A | Not a routine cost under any circumstance |
| Items or services not otherwise covered by Medicare outside the trial | Not Covered | N/A | Trial enrollment does not expand the Medicare benefit |
| Adverse event management arising from the investigational item | Covered (generally) | No specific codes listed in this policy | Treating side effects of the investigational item is typically a routine cost |
| Reasonable and necessary care for trial-related complications | Covered (generally) | No specific codes listed in this policy | Document clinical rationale; apply standard medical necessity criteria |
This policy does not list specific CPT, HCPCS, or ICD-10 codes. Coverage status applies across applicable codes based on the nature of the service.
CMS Clinical Trial Billing Guidelines and Action Items 2026
These are concrete steps your billing team needs to take before May 15, 2026. Don't treat this as a future project — the effective date is close, and clinical trial billing workflows take time to audit and correct.
| # | Action Item |
|---|---|
| 1 | Pull every open clinical trial at your organization and verify trial eligibility. Confirm each trial meets CMS qualifying criteria before you submit another claim for routine costs. If the trial doesn't qualify, Medicare is the wrong payer for any of those claims. Do this before April 30, 2026 to leave time for corrections. |
| 2 | Map every service line billed to trial patients and classify it. For each service, ask: would a Medicare beneficiary outside this trial receive this service? Does it meet medical necessity standards on its own? If the answer to either question is no, that service is not a routine cost under this coverage policy. |
| 3 | Audit your modifier use. CMS clinical trial billing requires the Q0 and Q1 modifiers in most cases. Q0 identifies services that are investigational (not covered). Q1 identifies routine costs in qualifying trials (covered). Swapping these — or omitting them — is one of the most common errors in clinical trial billing and a direct path to claim denial. |
| 4 | Review your documentation templates for medical necessity. Your notes for trial patients need to support medical necessity for each service independent of the trial. Work with your clinical staff to update visit documentation templates if they don't currently capture this clearly. Target completion: May 1, 2026. |
| 5 | Set up a secondary payer reconciliation process for trial-specific costs. Services that are not routine costs need to go to the trial sponsor. If your billing team is currently sending all trial-related claims to Medicare and letting denials sort it out, that process creates overpayment risk. Build a workflow that routes non-routine costs to the sponsor at the time of billing, not after a denial. |
| 6 | Talk to your compliance officer about your trial-specific billing audits. If you're running multiple trials across specialties, the risk surface is large. A targeted internal audit of the last 12 months of clinical trial claims is worth the investment before the May 15, 2026 effective date triggers closer CMS scrutiny. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Routine Costs in Clinical Trials Under This Policy
A Note on Code Coverage
This CMS policy does not list specific CPT, HCPCS, or ICD-10 codes. That is intentional — the policy applies horizontally across service types, not to a defined set of procedure codes.
Clinical trial routine costs billing spans nearly every code category: E&M visits, laboratory services, imaging, infusion, surgical procedures, and more. What determines coverage is not the code itself but whether the service represented by that code qualifies as a routine cost under the criteria above.
Modifier Use in Clinical Trial Billing
While the policy doesn't specify procedure codes, two modifiers are central to Medicare clinical trial billing and your team must apply them correctly:
| Modifier | Description | When to Use |
|---|---|---|
| Q0 | Investigational clinical service provided in a clinical research study | Use on services that are investigational — the item or service under study |
| Q1 | Routine clinical service provided in a clinical research study | Use on routine cost claims for qualifying clinical trial patients |
Misapplying these modifiers is the single most common clinical trial billing error. A Q0 service submitted to Medicare as the primary payer will deny — and should. A Q1 service without adequate medical necessity documentation will deny on audit if not at submission.
ICD-10 Context
ICD-10 codes in clinical trial billing serve two functions: they identify the underlying condition being treated (which supports medical necessity), and in some cases they identify trial participation. ICD-10-CM code Z00.6 (encounter for examination for normal comparison and control in clinical research program) is commonly used for healthy volunteers in trial visits. For patients receiving treatment in a trial, the diagnosis codes should reflect the patient's actual condition — not the trial itself.
This policy does not mandate specific ICD-10 codes. Use codes that accurately reflect the patient's diagnosis and support medical necessity for each service billed.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.